Dear Editor,

The Covid-19 pandemic have spread to 185 countries affecting almost 5 million patients worldwide with more than two million recovering and more than 300 thousand deaths globally as of 17th May \[[@bb0005]\].

The main cause of death is acute respiratory insufficiency with or without Acute Respiratory Distress syndrome (ARDS).

Recent evidence, over concurrent coagulation disorders, has emerged with reported cases of pulmonary embolism and clinical worsening due to disseminated intravascular coagulation (DIC) \[[@bb0010],[@bb0015]\]; moreover most reported thrombophilic conditions affecting these patients are acute pulmonary embolism (PE), deep-vein thrombosis (DVT), ischemic stroke, myocardial infarction or systemic arterial embolism and cerebral vein thrombosis without hemorrage \[[@bb0020],[@bb0025]\]; in consideration of these observations the administration of low-molecular-weight-heparin (LWMH) has been introduced recently as adjuvant therapy \[[@bb0030]\].

Moreover, evidence of central and peripheral neurological symptoms have been recently described in Covid-19 patients in Wuhan (30,2--45-5%) with higher prevalence in cases of severe pulmonary infection, with report of two cerebral hemorrhages (1,8%) \[[@bb0035]\]; in these series, heparin was not administered as support therapy.

From 20^th^-April to the 29th April, in 4 different hospitals in Italy, six (n=6) Covid-19 positive patients presented intraparenchymal cerebral hemorrhage related to cerebral vein thrombosis. Patients characteristics are summarized in [Table. 1](#t0005){ref-type="table"} .Table 1Patients characteristics, CT findings, neurological symptoms and therapeutical management. (I.U. International Unit).Table 1PatientAge (years)GenderICUThrombosis/hemorrhagic sitePrior LWMH therapy YES/NO (I.U.)SymptomsLWMH therapy after diagnosis (I.U.)164MYESRight parietal (Right transverse sinus and sagittal sinus)4000 × 2Epileptic Seizure8000 × 2275FNOLeft parietalNOHeadache, hemiplegia, TIA8000 × 2352MNORight parietal4000 × 2TIA, Headache8000 × 2465MYESRight parieto-occipital and temporal4000 × 2GCS 58000 × 2561FYESLeft parietal6000 × 2GCS 68000 × 2675FYESRight temporal6000 × 2ND for mechanical ventilation8000 × 2

In all patients an unhenaced CT scan was acquired and in 2 patients an adjunctive pre and post-contrast MRI was acquired. (see [Fig. 1](#f0005){ref-type="fig"} )Fig. 1A) and B) Unehnanced axial brain CT scan shows hyperdense appearance along the superior sagittal sinus with intracerebral hemorrhagic infarction in the right parietal and frontal lobes. C) CT sagittal reconstruction depicts the extension of sagittal sinus hyperdensity. D) and E) T2 GRE MRI confirms hemorrhagic foci in parietal and frontal lobes; to note the thrombosis of the superior sagittal sinus and right transverse sinus. F) T1-FFE 3D MRI after administration of contrast medium showed extension of thrombosis in sagittal sinus.Fig. 1

In 4 patients the site of hemorrhage was single; in 2 patients multiple sites were reported.

4 patients were in Intensive Care Unit (ICU) with mechanical ventilation and 1 patient was under oxygen support therapy; in the last patient, asymptomatic for respiratory alterations, cerebral hemorrhage was the first symptom discovered, with further development of typical lung CT patterns and positive Real-Time Reverse Transcriptase-Polymerase Chain Reaction assay for COVID-19 from the nasopharyngeal swab specimen.

Not-ICU patients presented the following symptoms: headache (100%) hemiplegia (50%), seizure (50%), TIA (50 %); in one of these patients, neurological symptoms (transient hemiplegia) were the first clinical alteration of COVID-19 infection.

In 5/6 patient LWMH was previously added in therapy prior to the diagnose of cerebral hemorrhage (at least 3 days before) at a dosage of 4000-6000 × 2. All patients implemented LMWH to therapeutical dosage (8000 × 2).

The only patient with a diagnose of cerebral hemorrhage as first symptom of Covid-19 disease started LWMH at a dosage of 8000 × 2. In two ICU-patients, diagnosis of neurological symptoms and cerebral hemorrhage was done at the time of attempt of extubation with clinical evidence of central neurological symptoms (GCS 6 and 5) that required re-intubation.

Any patients included in this series did not presented contemporary evidence of Pulmonary Thromboembolism.

It\'s has been recently discovered and discussed the prevalence of thrombotic events in COVID patients. Despite this evidence, to date, no reported case regarding cerebral hemorrhage due to cortical vein thrombosis had been described.

The observations of this clinical situation might have several implications:•In this emergency scenario, the availability of dedicated CT rooms and time-spot for radiological examination in Covid-19 patients led to organizational problem affecting Radiological Departments. Due to the high number of exams required and to the necessity of room disinfection protocol (around 1 h between every patient) the availability of CT-room can be reduced \[[@bb0040].In order to optimize patients care, and only in selected cases with pulmonary and neurological impairment, concomitant chest and brain CT scan might be helpful. These observations can play a pivot role, in particular in mechanically ventilated patients, due to the possible co-existence of acute hidden underlying neurological alteration. •Knowledge of incidence of cerebral hemorrhage linked to cerebral vein thrombosis matches the evidence of pro-coagulation disorders and DIC as co-factor in Covid-19 patients with corroboration of LWMH as an essential treatment; moreover, patients admitted in intensive care unit having higher thrombotic risk might benefit from LMWH therapy.

In conclusion, brain CT examination can be suggested in selected cases especially in ICU and mechanically ventilated patients without significantly increasing of time and radiation dose. The present protocol could help to avoid waste of resources in this emergency healthcare condition. Evidence described could also play a crucial role in clinical practice to detect rapidly and more accurately patients who require modification of LMVH therapy.
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